SGLT-2 inhibitors therapy was a protective factor against SARS-CoV-2 infection and against COVID-19 hospitalization while sulfonylurea and insulin therapies were COVID-19 hospitalization risk factors. Here, SLC5A2 is linked to COVID-19.